In the effort of developing strategies to fine-tune TIMP selectivity toward specific targets, a mutant TIMP was designed for selective MMP-14 inhibition, which blocked collagenase activity and CD44 shedding in cell culture models of breast cancer and fibrosarcoma [249]. Here, TIMP1 is linked to breast carcinoma.